PW Medtech Group Limited disclosed in its 3 September 2026 Next Day Disclosure Return that it repurchased 196,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HKD 0.93 to HKD 0.94 per share, for a total consideration of HKD 0.18 million. The shares, equal to 0.0137% of the company’s outstanding share capital, are intended for cancellation.

Including this latest transaction, the company has acquired 3.08 million shares for cancellation between 29 June and 3 September 2026. The cumulative volume represents 0.21% of the 1.43 billion shares in issue when the repurchase mandate was approved on 26 June 2026. Purchase prices during this period ranged from HKD 0.91 to HKD 1.10 per share.

Despite the ongoing buybacks, PW Medtech’s issued share capital remains at 1.43 billion shares, as none of the repurchased shares had been cancelled by the disclosure date. The current buyback tally utilises roughly 2.14% of the 144.29 million shares authorised under the June mandate, leaving capacity to repurchase up to about 141.20 million additional shares.

In line with Main Board Rule 10.06(3)(a), the company is subject to a moratorium on issuing new shares or transferring treasury shares until 3 October 2026.